Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 ...
Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:30 AM ESTCompany ParticipantsDavid Amsellem - MD & Senior ...
Vascarta Inc., is pleased to share results from a new study led by researchers at the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), with scientists at the ...
Morning Overview on MSN
Cancer drug boosted 20,000x in striking lab breakthrough
A new class of cancer drug has been pushed to an almost unimaginable level of potency in the lab, with researchers reporting ...
The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.
Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with ...
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback